EOD Regional Nodes
Notes
**Note 1:** **Regional nodes and nodes, NOS**
* Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in EOD Mets.
**Note 2:** **LAMN tumors**
* Nodal metastasis is very rare in low-grade appendiceal neoplasms (LAMN). If there is no mention of lymph nodes in the pathology report for a LAMN, code as none (000).
**Note 3:** **CLINICAL and PATHOLOGICAL codes**
* This schema has lymph node codes that are defined as **CLINICAL** assessment only or **PATHOLOGICAL** assessment only.
* **PATHOLOGICAL** assessment only code (300) is used when
* Any microscopic examination of regional lymph nodes, includes
* FNA, core biopsy, sentinel node biopsy or lymph node excision done during the clinical work up **AND/OR**
* Lymph node dissection performed
* Pathological code 300 takes priority over codes 450-700, 800
* **CLINICAL** assessment only codes (450-700) are used when the **only** information on nodal involvement is based on **physical exam or imaging**
* These codes are specifically for when there is no **microscopic confirmation** of regional lymph nodes (*Regional Nodes Positive = 98, 99*)
* **Note:** Use code 300 if *Regional Nodes Positive is 01-90, 95*
* Remaining codes (no designation of **CLINICAL** or **PATHOLOGICAL** only assessment) can be used based on clinical and/or pathological information
* **Code 000** is used when there is no evidence of regional lymph nodes clinically **OR** lymph nodes are negative pathologically (*Regional Nodes Positive = 00, 98*)
* **Code 800** is used when there are positive nodes (clinical or pathological), but the specific lymph nodes or number of positive nodes is unknown (*Regional Nodes Positive = 97*)
* **Code 999** is used when the lymph node status is unknown and *Regional Nodes Positive = 99*
**Note 4:** **Tumor Deposits**
* Code 400 is defined as **PATHOLOGICAL** assessment only. This is used when
* Primary tumor or site surgically resected with
* Any positive microscopic examination of tumor deposits WITHOUT positive lymph nodes
* If there are also positive lymph nodes, code 300
| Code |
Description |
SS2018 N |
| 000 |
No regional lymph node involvement |
NONE |
| 300 |
**PATHOLOGICAL ASSESSMENT ONLY**
- Cecal
+ Anterior (prececal)
* Posterior (retrocecal)
* Right colic
- Colic, NOS
- Epicolic (adjacent to bowel wall)
- Ileocolic
- Mesenteric, NOS
- Mesocolic, NOS
- Paracolic/pericolic |
RN |
| 400 |
**PATHOLOGICAL ASSESSMENT ONLY**
Tumor deposits (TD) in the subserosa, mesentery, mesorectal
or nonperitonealized pericolic or perirectal tissues
WITHOUT regional nodal metastasis |
RN |
| 450 |
**CLINICAL ASSESSMENT ONLY**
One positive node clinically OR Stated as Clinical N1a |
RN |
| 500 |
**CLINICAL ASSESSMENT ONLY**
Two-three positive nodes clinically OR Stated as Clinical N1b |
RN |
| 550 |
**CLINICAL ASSESSMENT ONLY**
Stated as Clinical N1, number of positive nodes clinically unknown |
RN |
| 600 |
**CLINICAL ASSESSMENT ONLY**
Four-six positive nodes clinically OR Stated as Clinical N2a |
RN |
| 650 |
**CLINICAL ASSESSMENT ONLY**
Seven or more positive nodes clinically OR Stated as Clinical N2b |
RN |
| 700 |
**CLINICAL ASSESSMENT ONLY**
Stated as Clinical N2, number of positive nodes clinically unknown |
RN |
| 800 |
Positive nodes, number unknown
Unknown if clinical or pathological assessment
Regional lymph node(s), NOS
Lymph node(s), NOS |
RN |
| 999 |
Unknown; regional lymph node(s) not stated
Regional lymph node(s) cannot be assessed
Not documented in medical record
Death Certificate Only |
U |
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998
(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.
(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)
(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
(5) Overman, M.J., Jessup, J.M., et al. **Appendix - Carcinoma**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
